Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MHRA (Medicines & Healthcare Products Regulatory Agency) puts weight behind Boston stent recall:

This article was originally published in Clinica

Executive Summary

The number of products affected in the UK by the global recall of certain batches of Boston Scientific's Taxus Express2 paclitaxel-eluting stent system and Express2 bare metal stent system are 26,000 and 15,000, respectively. So says the device alert issued by the Medicines and Healthcare products Regulatory Agency (MHRA) on July 23. The company has said that 85,000 and 11,000 units, respectively, were being recalled worldwide. UK healthcare providers have been issued with a July 29 deadline for receiving a recall notification from Boston. Failure to receive this will require that all products of these types be returned to the manufacturer.

You may also be interested in...



Senate Drug Pricing Bill Lowers Manufacturer Discounts In Part D Catastrophic Phase

Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.

Performance Criteria Issued On Magnetic Resonance Coils In New FDA Draft Guidance

Through a draft guidance, the US agency has established performance criteria for magnetic resonance coils, making the devices eligible for the standards-based Safety and Performance Based Pathway.

Global Scare Over Nitrosamine Impurities Extends To Diabetes Medication

Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.

Topics

UsernamePublicRestriction

Register

MT059220

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel